Literature DB >> 6173535

Cardiac effects of amrinone on rabbit papillary muscle and guinea pig Langendorff heart preparations.

G Onuaguluchi, R D Tanz.   

Abstract

Amrinone (50-1,000 microgram/ml) produces a dose-dependent inotropic action on rabbit papillary muscle. The hypodynamic state following prolonged stimulation is prevented or abolished by amrinone, and contractile force remains significantly elevated over drug-free controls throughout the ensuing 3-h duration of exposure. In a concentration of 1 mg/ml, dysrhythmic phenomena occasionally appeared, e.g., bigeminy, automaticity, and elevated threshold to electrical stimulation. Bigeminy could be abolished either by increasing the external K+ concentration in the bathing media, or by raising the stimulating voltage. However, amrinone failed to alter the refractory period following 60 min of exposure. In isolated perfused guinea pig Langendorff heart preparations, amrinone (50 microgram/ml) significantly increased coronary flow, myocardial oxygen consumption (MVO2), cardiac work, and, during the period of peak activity, dP/dt. However, it had no significant effect on cardiac efficiency. And, as in the papillary muscle preparation, the effect of amrinone was easily reversed by perfusing the preparation with fresh (no-drug) media. Preliminary evidence shows that amrinone fails to reverse the negative inotropic action of verapamil as well as calcium-free media, although the effects on heart rate, coronary flow, and MVO2 were reversed. However, the higher the external calcium concentration, the greater was the level of contractile response achieved by amrinone. Thus, the mechanism of amrinone-induced augmentation appears to be dependent upon the availability of calcium.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6173535     DOI: 10.1097/00005344-198111000-00022

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  7 in total

1.  Amrinone improves postischemic myocardial metabolism in the rat heart-lung preparation.

Authors:  Masaki Kume; Satoshi Kashimoto; Atsusi Furuya; Teruo Kumazawa
Journal:  J Anesth       Date:  1996-12       Impact factor: 2.078

2.  Effects of amrinone on cardiac contraction and relaxation in isolated, perfused rat heart.

Authors:  Y X Ma; H Y Zhao
Journal:  J Tongji Med Univ       Date:  1994

3.  Effects of amrinone on the transmembrane action potential of rabbit sinus node pacemaker cells.

Authors:  I Kodama; N Kondo; S Shibata
Journal:  Br J Pharmacol       Date:  1983-11       Impact factor: 8.739

4.  Non-additive positive inotropic effects of amrinone and ouabain on cat papillary muscles.

Authors:  L Brown; E Erdmann
Journal:  Klin Wochenschr       Date:  1984-05-02

Review 5.  Amrinone. A preliminary review of its pharmacological properties and therapeutic use.

Authors:  A Ward; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-12       Impact factor: 9.546

6.  Comparison of the effects of amrinone and sodium nitroprusside on haemodynamics, contractility, and myocardial metabolism in patients with cardiac failure due to coronary artery disease and dilated cardiomyopathy.

Authors:  P T Wilmshurst; D S Thompson; S M Juul; B S Jenkins; D J Coltart; M M Webb-Peploe
Journal:  Br Heart J       Date:  1984-07

7.  Effects of intracoronary and intravenous amrinone infusions in patients with cardiac failure and patients with near normal cardiac function.

Authors:  P T Wilmshurst; D S Thompson; S M Juul; H C Dittrich; J R Dawson; J M Walker; B S Jenkins; D J Coltart; M M Webb-Peploe
Journal:  Br Heart J       Date:  1985-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.